Data show the world’s first EMA-approved biosimilar monoclonal antibody Remsima™ could reduce cost of treating Crohn’s disease by up to €336 million over five years
23 February 2015 | By Celltrion Healthcare
Cost savings could help improve patient access to life-changing treatment...